Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Observational Study to Observe the Efficacy of Levemir® (Insulin Detemir) in Patients With Type 2 Diabetes.
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1074
- Registration Number
- NCT00793273
Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 102
- Registration Number
- NCT00791895
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3131
- Registration Number
- NCT00789711
- Locations
- 🇵🇭
Novo Nordisk Investigational Site, Manilla, Philippines
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Indonesia
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Other: No treatment given
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1832
- Registration Number
- NCT00788853
Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 222
- Registration Number
- NCT00789191
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Kocaeli, Turkey
Long Term Metabolic Safety of Norditropin® Treatment of Small for Gestational Age (SGA) Subjects
Completed
- Conditions
- Foetal Growth ProblemSmall for Gestational Age
- Interventions
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 153
- Registration Number
- NCT00787878
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Rotterdam, Netherlands
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
Phase 3
Completed
- Conditions
- ObesityMetabolism and Nutrition Disorder
- Interventions
- Drug: placebo
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 422
- Registration Number
- NCT00781937
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Montreal, Canada
Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 611
- Registration Number
- NCT00775736
- Locations
- 🇱🇺
Novo Nordisk Investigational Site, Luxembourg, Luxembourg
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2Delivery Systems
- Interventions
- Device: FlexTouch®Device: FlexPen®
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 242
- Registration Number
- NCT00773279
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10408
- Registration Number
- NCT00771680
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Kiev, Ukraine
© Copyright 2025. All Rights Reserved by MedPath